The DOI matches its Crossref record; 222 of the 224 references it cites were found in a registry or an index; 43 of the 250 sources its claims cite were checked for support.
Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers
Open accessAbstract
Ketamine, a drug introduced in the 1960s as an anesthetic agent and still used for that purpose, has garnered marked interest over the past two decades as an emerging treatment for major depressive disorder. With increasing evidence of its efficacy in treatment-resistant depression and its potential anti-suicidal action, a great deal of investigation has been conducted on elucidating ketamine’s effects on the brain. Of particular interest and therapeutic potential is the ability of ketamine to exert rapid antidepressant properties as early as several hours after administration. This is in stark contrast to the delayed effects observed with traditional antidepressants, often requiring several weeks of therapy for a clinical response. Furthermore, ketamine appears to have a unique mechanism of action involving glutamate modulation via actions at the N-methyl-D-aspartate (NMDA) and [Formula: see text]-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, as well as downstream activation of brain-derived neurotrophic factor (BDNF) and mechanistic target of rapamycin (mTOR) signaling pathways to potentiate synaptic plasticity. This paper provides a brief overview of ketamine with regard to pharmacology/pharmacokinetics, toxicology, the current state of clinical trials on depression, postulated antidepressant mechanisms and potential biomarkers (biochemical, inflammatory, metabolic, neuroimaging sleep-related and cognitive) for predicting response to and/or monitoring of therapeutic outcome with ketamine.
Overview
CoChat Summary
TL;DR
This review summarizes ketamine’s pharmacology, clinical trial evidence, adverse effects, antidepressant mechanisms, and candidate biomarkers for treatment-resistant depression. It highlights rapid but transient antidepressant and anti-suicidal effects, with a proposed glutamate–AMPA–BDNF–mTORC1 synaptic plasticity mechanism, while noting limited long-term and biomarker data.
Key findings
- Ketamine produces rapid antidepressant effects within 2–4 h, with 60–70% response rates in treatment-resistant depression (TRD); effects are transient, lasting an average of 1 week after a single infusion and 18–19 days after repeated infusions. Retrospective real-world data showed a 44% response rate after six intravenous ketamine treatments in complex, ultra-resistant patients.
- Its mechanism is more complex than NMDA receptor antagonism: ketamine preferentially antagonizes NMDA receptors on GABA interneurons, causing disinhibition of glutamatergic neurons, a glutamate surge, AMPA receptor activation, and downstream BDNF/mTORC1 signaling that potentiates synaptic plasticity. Other NMDA antagonists such as memantine, lanicemine, and nitrous oxide do not exert consistent antidepressant effects.
- Candidate biomarkers include plasma BDNF elevations in responders, reduced response in BDNF Val66Met carriers, plasma D-serine levels predicting response, sleep slow-wave activity increases, pro-cognitive effects at TRD doses, inflammatory/metabolic markers (IL-6, CRP, hsCRP, TNF-α, adiponectin, resistin, BMI, metabolic syndrome), and neuroimaging findings in prefrontal cortex, anterior cingulate cortex, hippocampus, and nucleus accumbens.
- Intranasal esketamine was FDA-approved in March 2019 for major depression failing two or more antidepressants; a phase III trial of over 200 patients showed significant improvement at 4 weeks, while two other phase III trials failed primary endpoints. Maintenance studies up to 88 weeks reported decreased relapse risk and reassuring safety data to over 1 year.
Methods
- Narrative review of ketamine as an antidepressant, covering pharmacology/pharmacokinetics, clinical trials, adverse effects, postulated mechanisms, and potential biomarkers.
- Literature search performed in PubMed/MEDLINE and Web of Science Core Collection for English-language papers from 2000 to 2019, using specified topics such as ketamine as an antidepressant, mechanisms of action, biomarkers, enantiomers/metabolites, inflammation, metabolism, sleep, adverse effects, cognition, and neuroimaging.
- Synthesis is qualitative; no systematic review, meta-analysis, or formal quality appraisal is described.
Limitations
- Stated in the paper: no long-term RCTs exist; many studies have small sample sizes; findings are contradictory for some mechanisms and biomarkers (e.g., 2R,6R-HNK, mTOR/rapamycin, opioid system); large head-to-head clinical comparisons of esketamine, R-ketamine, and racemic ketamine have not been reported; sleep data are limited to short-term intravenous infusions; neuroimaging data are limited by small samples and few investigations.
- Evident from the text: as a narrative review, it does not systematically assess study quality or pool results quantitatively, and much mechanistic evidence comes from animal models, so biomarker and mechanism conclusions remain preliminary.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
22 Valid · 3 Not valid · 124 Not checked · 31 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Following treatment with antidepressant drugs, only half of patients are noted to have a significant clinical response.6,7”
§ Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers > Introduction
What the sources say
- Supportedcites [6] Undurraga J Baldessarini RJ Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review. Neuropsychopharmacology 2012; 37: 851– 864. 22169941 PMC3280655 source
The Discussion reports a 54% crude response rate among participants receiving antidepressants in the reviewed trials, consistent with “only half.” The Outcome Measures section defines response as usually at least a 50% reduction in depression rating-scale scores. This finding concerns adults in trials for acute major depression. (LLM, conf=0.92)
- Not checked yetcites [7] Fava M Davidson KG Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 1996; 19: 179– 200. 8827185 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A phase III trial of over 200 patients using esketamine adjunctive to an antidepressant demonstrated significant improvement in depression at 4 weeks compared with those using a placebo nasal spray.70”
§ Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers > Overview of the status of clinical trials with ketamine and its enantiomers
What the sources say
- Supportedcites [70] Popova V Daly EJ Trivedi M, et al Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry 2019; 176: 428– 438. 31109201 source
The opening Results passage reports that 227 patients were randomized. The Results section reports significantly greater improvement in depression scores at day 28 with esketamine plus an oral antidepressant than with an oral antidepressant plus placebo nasal spray (p=0.020). The Discussion identifies this as a phase 3 study. Page numbers were not supplied in our copy. (LLM, conf=0.93)
boostedstates a causen = 200- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“However, the literature on the antidepressant effects of 2R,6R-HNK is controversial, with several contradictory reports.41,48–52”
§ Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers > Basic chemistry, pharmacology and pharmacokinetics of ketamine
What the sources say
- Supportedcites [41] Yang C Yang J Luo A, et al Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites. Transl Psychiatry 2019; 9: 280. PMC6838457 31699965 source
The (2R,6R)-HNK section (page not supplied) reports that several groups replicated its antidepressant-like effects in rodents, but the authors' group found no such effects in rodent models of depression. Those opposing findings support the description of the literature as controversial. (LLM, conf=0.93)
- Supportedcites [48] Zanos P Highland JN Liu X, et al (R)-ketamine exerts antidepressant actions partly via conversion to (2R,6R)-hydroxynorketamine, while causing adverse effects at sub-anaesthetic doses. Br J Pharmacol 2019; 176: 2573– 2592. 30941749 PMC8567221 source
The Discussion reports several studies finding rapid antidepressant-relevant actions of (2R,6R)-HNK and contrasts them with studies that failed to find such actions in animal tests. It also discusses dose differences as a possible explanation for the conflicting results. (LLM, conf=0.91)
- Supportedcites [49] Fukumoto K Fogaca MV Liu RJ, et al Activity-dependent brain-derived neurotrophic factor signaling is required for the antidepressant actions of (2R,6R)-hydroxynorketamine. Proc Natl Acad Sci USA 2019; 116: 297– 302. 30559184 PMC6320534 source
The Discussion explicitly notes discrepancies among reports of (2R,6R)-HNK’s antidepressant actions, particularly in stress and social-defeat models. It also says the reasons for those discrepancies are unclear. (LLM, conf=0.91)
- Not checked yetcites [50] Chou D Peng HY Lin TB, et al (2R,6R)-hydroxynorketamine rescues chronic stress-induced depression-like behavior through its actions in the midbrain periaqueductal gray. Neuropharmacology 2018; 139: 1– 12. 29953886 source
- Not checked yetcites [51] Xiong Z Fujita Y Zhang K, et al Beneficial effects of (R)-ketamine, but not its metabolite (2R,6R)-hydroxynorketamine, in the depression-like phenotype, inflammatory bone markers, and bone mineral density in a chronic social defeat stress model. Behav Brain Res 2019; 368: 111904. 30980851 source
- Supportedcites [52] Yamaguchi JI Toki H Qu Y, et al (2R,6R)-hydroxynorketamine is not essential for the antidepressant actions of (R)-ketamine in mice. Neuropsychopharmacology 2018; 43: 1900– 1907. 29802366 PMC6046044 source
The Introduction describes opposing reports on whether (2R,6R)-HNK has antidepressant effects in rodent models. The Discussion explicitly says the study's results contradict previously reported results and notes discrepancies between laboratories. Page numbers are not provided in our copy. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“This increase in SWA correlates strongly with increases in synaptic plasticity and plasma BDNF preclinically,135 and in ketamine-responsive MDD patients.113,133”
§ Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers > Other potential biomarkers for predicting response to ketamine > Sleep
What the sources say
- Not checked yetcites [135] Huber R Tononi G Cirelli C Exploratory behavior, cortical BDNF expression, and sleep homeostasis. Sleep 2007; 30: 129– 139. 17326538 source
- Supportedcites [113] Duncan WC Sarasso S Ferrarelli F, et al Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder. Int J Neuropsychopharmacol 2013; 16: 301– 311. 22676966 PMC3510337 source
The Results section 'Relationship between mood, BDNF, and slow wave sleep changes' reports that in the ketamine-responder subgroup (N=13) SWA (r=0.595, p=0.032) and slow wave amplitude (r=0.626, p=0.022) correlated significantly with change in log plasma BDNF, whereas non-responders (N=16) showed no such relationships; the whole-group correlation was r=0.45, p=0.014. The Abstract and Discussion frame SWA and individual slow wave parameters as surrogate markers of central synaptic plasticity/synaptic strength and state that the BDNF–slow wave link 'was strongest in the cohort of responders', supporting the claim's wording that SWA increases correlate with increases in synaptic plasticity and plasma BDNF in ketamine-responsive MDD patients. Only the magnitude adverb 'strongly' is slightly stronger than the paper's own 'significant/proportional/strongest in responders' language (r ≈ 0.6), and the preclinical clause of the citing sentence is attributed to a different reference (135), not this paper. (LLM, conf=0.84)
- Supportedcites [133] Duncan WC Jr Zarate CA Jr Ketamine, sleep, and depression: current status and new questions. Curr Psychiatry Rep 2013; 15: 394. 23949569 PMC3827949 source
The 'Effects of Ketamine on Sleep and Slow Waves in Treatment-Resistant MDD' section states that in patients who responded to ketamine (>50% MADRS reduction), 'changes in BDNF levels were proportional to changes in EEG slow wave parameters,' and that 'the observed correlations between BDNF levels and slow wave parameters indicate a strong relationship between these measures,' with slow wave slope increases 'consistent with increased synaptic strength.' The 'Sleep and Plasticity' section supplies the preclinical side: SWA is raised by intrahemispheric BDNF infusion and by behavioral interventions that increase central BDNF and plasticity-related genes (refs 9, 28), with SWA/slow wave slope treated as markers of synaptic strength. Both halves of the paraphrase — preclinical and ketamine-responsive MDD — are therefore carried by our copy of this review. (LLM, conf=0.87)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“AMPA receptor activation appears to be a critical step in ketamine’s mechanism of action as co-administration of an AMPA receptor inhibitor abolished its antidepressant effects.96–98”
§ Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers > Antidepressant mechanisms of ketamine and potential biochemical biomarkers
What the sources say
- Supportedcites [96] Autry AE Adachi M Nosyreva E, et al NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 2011; 475: 91– 95. 21677641 PMC3172695 source
Passage [3] states that acute systemic NBQX alone did not affect forced-swim behaviour, but when co-applied with ketamine it 'abolished behavioural FST AD-like responses', and concludes that the behavioural antidepressant effects 'require ketamine-mediated augmentation of AMPA-receptor activation'. Passage [1] reinforces this ('increased AMPA-mediated neurotransmission underlies ketamine's AD-like behavioural effects'). The citing sentence is hedged ('appears to be a critical step'), which the source supports with equal or greater confidence. (LLM, conf=0.90)
- Not checked yetcites [97] Koike H Iijima M Chaki S Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behav Brain Res 2011; 224: 107– 111. 21669235 source
- Not checked yetcites [98] Maeng S Zarate CA Jr Du J, et al Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 2008; 63: 349– 352. 17643398 source
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
96 more claims · 6 with their cited sources checked
Create a free account to see all 180 claims and to verify the 206 references still open.
- It may state two separate claims as one. 61
- Probably not a substantial claim. 26
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition to glutamatergic modulation, ketamine is also an opioid (mu, kappa, delta) and dopamine receptor agonist, inhibits monoamine reuptake, and antagonizes muscarinic receptors [32].”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [32]
Experimental — accuracy not yet measured
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
mTOR Signaling in Growth, Metabolism, and Disease
Saxton, R. A., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.02.004 · Cited by 7,555
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Ferrari, A. J., Charlson, F. J., Norman, R. E., Patten, S. B., Freedman, G., Murray, C. J. L., Vos, T., & Whiteford, H. A. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001547 · Cited by 3,115 · cited 2×
“an option for increasing accessibility of ketamine treatments for depression? J Clin Psychiatry 2020; 81(1): 19lr13146.”
BackgroundmTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
mTOR Signaling in Growth, Metabolism, and Disease
Saxton, R. A., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.03.035 · Cited by 2,070
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
NMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609
Research works printed but not linked: 16
- Baker G, 2009, Wiley encyclopedia of chemical biology
- 10.1177/2045125316631267 · DOI · Paper page
- Tan Y, 2019, Pharmacol Biochem Behav, 188
- Albott CS, 2018, J Clin Psychiatry, 79
- Rosenblat JD, 2019, J Clin Psychiatry, 80
- Meisner R, 2019, Harvard Health Blog
- Wlodarczyk A, 2019, Psychiatr Danub, 31, 530
- Szarmach J, 2019, Psychiatr Danub, 31, 585
- Dong C, 2017, Int J Neuropsychopharmacol, 20, 228
- Moda-Sava RN, 2019, Science, 364
- Abdallah CG, bioRxiv, 2018
- Singh NS, 2016, PLoS One, 11
- Wu C, 2019, Neurobiol Learn Mem, 167
- Godin O, 2019, J Clin Psychiatry, 80
- Rong C, 2018, Int J Environ Res Public Health, 15
- Abdallah CG, 2018, Chronic Stress (Thousand Oaks, Calif), 2
Cited by
Treatment of Posttraumatic Stress Disorder: A State-of-the-art Review
Burback, L., Brémault-Phillips, S., Nijdam, M. J., McFarlane, A., & Vermetten, E. (2024) · Current Neuropharmacology · doi:10.2174/1570159x21666230428091433 · Cited by 208
Donoso, F., Cryan, J. F., Olavarría‐Ramírez, L., Nolan, Y. M., & Clarke, G. A. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2581 · Cited by 159
Cutler, A. J., Mattingly, G. W., & Maletic, V. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02514-2 · Cited by 190
“Increased extracellular glutamate initiates activation of postsynaptic AMPA receptors, leading to potentiation of BDNF and mTORC1 synaptogenic signaling pathways (Table 1) [190, 204, 205].”
BackgroundMartinotti, G., Chiappini, S., Pettorruso, M., Mosca, A., Miuli, A., Carlo, F. D., d’Andrea, G., Collevecchio, R., Muzio, I. D., Sensi, S. L., et al. (2021) · Brain Sciences · doi:10.3390/brainsci11070856 · Cited by 125
“Not recorded Veraart et al., 2020 [13] 1 F (55 years old) Oral esketaminetreatment NA Oral esketamine treatment started at 0.5 mg/kg twice weekly and was titrated to 2.0 mg/kg 6 weeks MDD who previously was resistant to ECT and DBS comorbid with psychotic and obsessive symptoms Venlafaxine 300 mg; Clozapine 450 mg; Gl…”
BackgroundInfluentialNeurobiological Basis of Increased Risk for Suicidal Behaviour
Wisłowska-Stanek, A., Kołosowska, K., & Maciejak, P. (2021) · Cells · doi:10.3390/cells10102519 · Cited by 139
Metadata
- Authors
- Matveychuk, D., Thomas, R. K., Swainson, J., Khullar, A., MacKay, M.-A., Baker, G. B., & Dursun, S. M.
- Affiliations
- University of Alberta (CA)
- Corresponding author
- Baker, Glen B.
- Venue
- Therapeutic Advances in Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2020-01
- Volume
- 10
- Pages
- 2045125320916657-2045125320916657
- ISSN
- 2045-1253 (ISSN-L)
- 2045-1261
- PMC
- PMC7225830
- OpenAlex
- W3025130047
- Cited by
- 209
- References
- 224
- Citations by year
- 2026: 24 · 2025: 27 · 2024: 59 · 2023: 33 · 2022: 41 · 2021: 22 · 2020: 3
- FWCI
- 14.83
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Therapeutic Advances in Psychopharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- university of alberta (TRPGB-UAB)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- ketamine, major depressive disorder, treatment-resistant depression, rapid antidepressant effects, NMDA receptor, AMPA receptors, glutamate modulation, brain-derived neurotrophic factor, mTOR signaling, synaptic plasticity, predictive biomarkers, antidepressant response prediction, suicide prevention, neuroimaging biomarkers, cognitive biomarkers, inflammatory markers, metabolic biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers. https://app.cochat.ai/papers/10.1177/2045125320916657
- The paper
- Matveychuk, D., Thomas, R. K., Swainson, J., Khullar, A., MacKay, M.-A., Baker, G. B., & Dursun, S. M. (2020). Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers. Therapeutic Advances in Psychopharmacology. https://doi.org/10.1177/2045125320916657
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
